{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T10:50:36Z","timestamp":1782125436070,"version":"3.54.5"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and hypothesis<\/jats:title>\n                    <jats:p>Hyperkalaemia is common and potentially life-threatening in individuals with chronic kidney disease (CKD). While sodium zirconium cyclosilicate (SZC) is used in the hospital setting for hyperkalaemia management, few patients are discharged with a continuing prescription, leaving them at risk of recurrent hyperkalaemia and rehospitalization. The CONTINUITY study aimed to establish the efficacy of continuing post-hospital discharge treatment with SZC versus standard of care (SOC) in maintaining normokalaemia and reducing all-cause and hyperkalaemia-related hospital admissions and emergency department visits in patients with CKD and hyperkalaemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This phase 4, randomized, controlled, open-label, parallel-group (multicentre study 28 sites; six European countries; 24 March 2022\u201310 December 2024), included participants aged \u226518 years admitted to hospital with diagnosed CKD (any stage) and hyperkalaemia [serum potassium (sK+) &amp;gt;5.0 and \u22646.5\u00a0mmol\/l] without ongoing K+ binder treatment. Participants received SZC for 2\u201321 days to normalize sK+. Those with normokalaemia (3.5\u20135.0\u00a0mmol\/l) at discharge were randomized to SZC or SOC. The primary objective was occurrence of normokalaemia at 180 days post-discharge [those achieving normokalaemia (responders) vs those who did not (non-responders)].<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The difference between arms for normokalaemia responders was not statistically significant: 30.9% (SZC) and 36.2% (SOC) (odds ratio 0.81; 95% CI 0.39\u20131.66; P = .558). High and imbalanced levels of missing sK+ measurements at 180 days [n = 35 (51.5%) in the SZC arm and n = 25 (36.2%) in the SOC arm] led to substantially lower levels of normokalaemia response than the original assumptions in the sample size calculations used to power the study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The study did not meet its primary endpoint. Study design limitations may have masked true treatment effects. Post hoc analyses revealed positive trends in SZC use and potential for reducing rehospitalization and enabling renin-angiotensin-aldosterone system inhibitor therapy continuation at optimal doses.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ckj\/sfag158","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T11:34:42Z","timestamp":1779190482000},"source":"Crossref","is-referenced-by-count":0,"title":["Sodium zirconium cyclosilicate post hospital discharge to prevent hyperkalaemia: phase 4, randomized CONTINUITY trial"],"prefix":"10.1093","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1176-7592","authenticated-orcid":false,"given":"James O","family":"Burton","sequence":"first","affiliation":[{"name":"Division of Cardiovascular Sciences, University of Leicester and University Hospitals of Leicester , Leicester ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda J","family":"Izquierdo","sequence":"additional","affiliation":[{"name":"Head of Nephrology Department, University Hospital of Burgos , Burgos ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Linde","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Karolinska Institutet , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol\u00e1s R","family":"Robles","sequence":"additional","affiliation":[{"name":"Universidad de Extremadura, Head Nephrology Department and Hypertension Unit, Hospital Universitario de Badajoz , Badajoz ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish M","family":"Sood","sequence":"additional","affiliation":[{"name":"Ottawa Hospital Research Institute, The Ottawa Hospital , Ottawa ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaster M","family":"Allum","sequence":"additional","affiliation":[{"name":"BioPharmaceuticals Medical, AstraZeneca , Cambridge ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M","family":"Eudicone","sequence":"additional","affiliation":[{"name":"BioPharmaceuticals Medical Evidence, AstraZeneca , Wilmington, DE ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Dahl","sequence":"additional","affiliation":[{"name":"BioPharmaceuticals Medical, AstraZeneca , Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alpesh N","family":"Amin","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California Irvine , Irvine, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"2026062206120118600_bib1","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.kisu.2017.09.001","article-title":"New options for the management of chronic hyperkalemia","volume":"7","author":"Fried","year":"2017","journal-title":"Kidney Int Suppl (2011)"},{"key":"2026062206120118600_bib2","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1007\/s40265-021-01555-5","article-title":"Hyperkalemia in chronic kidney disease in the new era of kidney protection therapies","volume":"81","author":"Valdivielso","year":"2021","journal-title":"Drugs"},{"key":"2026062206120118600_bib3","doi-asserted-by":"publisher","first-page":"iii12","DOI":"10.1093\/ndt\/gfz231","article-title":"Hyperkalemia in patients with chronic renal failure","volume":"34","author":"Seliger","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"2026062206120118600_bib4","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1007\/s10238-024-01452-7","article-title":"The burden of hyperkalaemia on hospital healthcare resources","volume":"24","author":"Logan\u00a0Ellis","year":"2024","journal-title":"Clin Exp Med"},{"key":"2026062206120118600_bib5","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1093\/ckj\/sfab029","article-title":"Adverse clinical outcomes associated with RAAS inhibitor discontinuation: analysis of over 400 000 patients from the UK Clinical Practice Research Datalink (CPRD)","volume":"14","author":"Humphrey","year":"2021","journal-title":"Clin Kidney J"},{"key":"2026062206120118600_bib6","doi-asserted-by":"publisher","first-page":"sfaf127","DOI":"10.1093\/ckj\/sfaf127","article-title":"The burden of hyperkalaemia in chronic kidney disease: a systematic literature review","volume":"18","author":"Floege","year":"2025","journal-title":"Clin Kidney J"},{"key":"2026062206120118600_bib7","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1053\/j.ajkd.2015.10.011","article-title":"Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials","volume":"67","author":"Xie","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"2026062206120118600_bib8","doi-asserted-by":"publisher","first-page":"378","DOI":"10.14744\/ejmi.2023.50258","article-title":"Hyperkalemia and use of RAAS inhibitors in stage 3-5 chronic kidney disease non-dialysis patients: a single-center experience","volume":"7","author":"Karaca","year":"2023","journal-title":"Eurasian J Med Invest"},{"key":"2026062206120118600_bib9","first-page":"S212","article-title":"Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors","volume":"21","author":"Epstein","year":"2015","journal-title":"Am J Manag Care"},{"key":"2026062206120118600_bib10","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.kisu.2016.01.004","article-title":"Hyperkalemia constitutes a constraint for implementing renin-angiotensin-aldosterone inhibition: the widening gap between mandated treatment guidelines and the real-world clinical arena","volume":"6","author":"Epstein","year":"2016","journal-title":"Kidney Int Suppl (2011)"},{"key":"2026062206120118600_bib11","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","journal-title":"Kidney Int"},{"key":"2026062206120118600_bib12","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12882-022-03054-5","article-title":"Clinical impact of suboptimal RAASi therapy following an episode of hyperkalemia","volume":"24","author":"Kanda","year":"2023","journal-title":"BMC Nephrol"},{"key":"2026062206120118600_bib13","doi-asserted-by":"publisher","first-page":"e012655","DOI":"10.1161\/JAHA.119.012655","article-title":"Real-world associations of renin-angiotensin-aldosterone system inhibitor dose, hyperkalemia, and adverse clinical outcomes in a cohort of patients with new-onset chronic kidney disease or heart failure in the United Kingdom","volume":"8","author":"Linde","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"2026062206120118600_bib14","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1093\/ndt\/gfae016","article-title":"Hyperkalaemia-related reduction of RAASi treatment associates with more subsequent inpatient care","volume":"39","author":"Svensson","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"2026062206120118600_bib15","doi-asserted-by":"publisher","first-page":"e114686","DOI":"10.1371\/journal.pone.0114686","article-title":"Characterization of structure and function of ZS-9, a K+ selective ion trap","volume":"9","author":"Stavros","year":"2014","journal-title":"PLoS One"},{"key":"2026062206120118600_bib16","first-page":"54","article-title":"Efficacy and safety of sodium zirconium cyclosilicate for hyperkalaemia: the randomized, placebo-controlled HARMONIZE-Global study","volume":"7","author":"Zannad","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2026062206120118600_bib17","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1093\/ndt\/gfz285","article-title":"Long-term safety and efficacy of sodium zirconium cyclosilicate for hyperkalaemia in patients with mild\/moderate versus severe\/end-stage chronic kidney disease: comparative results from an open-label, phase 3 study","volume":"36","author":"Roger","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"2026062206120118600_bib18","doi-asserted-by":"publisher","first-page":"798","DOI":"10.2215\/CJN.12651018","article-title":"Sodium zirconium cyclosilicate among individuals with hyperkalemia: a 12-month phase 3 study","volume":"14","author":"Spinowitz","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026062206120118600_bib19","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1080\/13696998.2025.2487357","article-title":"The role of sodium zirconium cyclosilicate drug utilization in managing hyperkalemia: impact on healthcare resource utilization and on maintenance of renin-angiotensin-aldosterone system inhibitor therapy in Italian clinical practice","volume":"28","author":"Gnesi","year":"2025","journal-title":"J Med Econ"},{"key":"2026062206120118600_bib20","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1007\/s12325-023-02518-w","article-title":"Real-world modifications of renin-angiotensin-aldosterone system inhibitors in patients with hyperkalemia initiating sodium zirconium cyclosilicate therapy: the OPTIMIZE I study","volume":"40","author":"Agiro","year":"2023","journal-title":"Adv Ther"},{"key":"2026062206120118600_bib21","doi-asserted-by":"publisher","first-page":"3960","DOI":"10.1007\/s12325-025-03254-z","article-title":"Renin-angiotensin-aldosterone system inhibitor dosing after initiation of outpatient sodium zirconium cyclosilicate therapy: the GALVANIZE RAASi real-world evidence study","volume":"42","author":"Agiro","year":"2025","journal-title":"Adv Ther"},{"key":"2026062206120118600_bib22","article-title":"ClinicalTrials.gov. NCT05347693, Continuing Sodium Zirconium Cyclosilicate (SZC) After Discharge Study (CONTINUITY)"},{"key":"2026062206120118600_bib23","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1093\/ckj\/sfad053","article-title":"Rationale and design of CONTINUITY: a Phase 4 randomized controlled trial of continued post-discharge sodium zirconium cyclosilicate treatment versus standard of care for hyperkalemia in chronic kidney disease","volume":"16","author":"Burton","year":"2023","journal-title":"Clin Kidney J"},{"key":"2026062206120118600_bib24","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.clinthera.2024.07.004","article-title":"HARMONIZE Asia: a Phase III randomized study to investigate the efficacy and safety of sodium zirconium cyclosilicate in patients with hyperkalemia in China","volume":"46","author":"Liang","year":"2024","journal-title":"Clin Ther"},{"key":"2026062206120118600_bib25","doi-asserted-by":"publisher","first-page":"sfae083","DOI":"10.1093\/ckj\/sfae083","article-title":"Maintained renin\u2013angiotensin\u2013aldosterone system inhibitor therapy with sodium zirconium cyclosilicate following a hyperkalaemia episode: a multi-country cohort study","volume":"17","author":"Rastogi","year":"2024","journal-title":"Clin Kidney J"},{"key":"2026062206120118600_bib26","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1080\/21548331.2021.1925554","article-title":"Inpatient management and post-discharge outcomes of hyperkalemia","volume":"49","author":"Davis","year":"2021","journal-title":"Hosp Pract (1995)"},{"key":"2026062206120118600_bib27","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1016\/j.ekir.2020.06.004","article-title":"Postdischarge health care costs and readmission in patients with hyperkalemia-related hospitalizations","volume":"5","author":"Betts","year":"2020","journal-title":"Kidney Int Rep"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfag158\/68335047\/sfag158.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/6\/sfag158\/68335047\/sfag158.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/6\/sfag158\/68335047\/sfag158.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T10:12:26Z","timestamp":1782123146000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfag158\/8687403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfag158","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,5,19]]},"article-number":"sfag158"}}